

# Dog NGAL ELISA Kit

EN

**KIT 043**



**BIOPORTO**<sup>®</sup>  
Diagnostics

**Revision: DN2011-01-EN**

**Please read these instructions carefully**

### INTENDED USE

For the *in-vitro* determination of dog NGAL in urine, plasma or serum, tissue extracts or culture media. For research use only.

### INTRODUCTION

NGAL (neutrophil gelatinase-associated lipocalin)<sup>1</sup> belongs to the lipocalin family of proteins<sup>2</sup>. These are small secreted proteins characterized by their ability i) to bind small hydrophobic molecules in a structurally conserved pocket formed by  $\beta$ -pleated sheet, ii) to bind to specific cell-surface receptors, and iii) to form macromolecular complexes. NGAL has many synonyms: perhaps the most widely used is lipocalin 2 (LCN 2); more recently the name siderocalin has been used to express NGAL's ability to bind bacterial siderophores<sup>3</sup>. As NGAL was first reported as oncogene 24p3 in the mouse<sup>4,5</sup>, this name is still occasionally used to identify NGAL in other species.

The NCBI reference sequence XM\_548441.2 from automated genome shotgun sequencing of *Canis lupus familiaris* (chromosome 9) suggests that dog NGAL consists of a single disulfide-bridged polypeptide chain of 178 amino-acid residues with a calculated molecular mass of 20.7 kDa. By analogy with NGAL from other mammalian species, glycosylation is expected to increase its apparent molecular mass on SDS-PAGE to about 24-25 kDa. The *N*-glycosylation site at residue 65 is intact and is in fact conserved in all the mammalian NGAL sequences known.

Because dog NGAL has not yet been isolated and no antibodies or immunochemical detection methods have hitherto been developed to detect or measure it, there are no published data on the physiological or pathological functions of this protein in the dog. However, it is likely that some features of the biosynthesis, location and release of dog NGAL will be similar to those of its homologues in other species. The present kit has in fact been developed to extend NGAL research and the use of NGAL as a marker molecule, especially for kidney injury, to

the dog. In the following, some pathophysiological features of NGAL in other mammalian species will be mentioned, because similar features may be observed in the dog.

Like other mammalian NGALs, dog NGAL may in certain situations be co-expressed and form complexes with matrix metalloproteinase-9 (MMP-9)<sup>6,7</sup>. Dog NGAL may also prove to form homodimers and higher oligomers with itself. As dog NGAL, unlike its human homologue but like all other mammalian NGALs known, does not possess a third cysteinyl residue capable of forming an intermolecular disulfide bridge, any complex formation detected will probably depend on non-covalent forces, at least initially.

In other mammals, NGAL is expressed in neutrophil polymorphonuclear leucocytes<sup>1</sup> and at lower basal levels in various other cell types, tissues or organs. These include epithelial cells of the uterus, mammary gland, lung, spleen, vagina and epididymis<sup>8-10</sup>. It may be expressed in additional cell types during embryonic development and in response to various stimuli. This applies to certain kidney cells (see below), LPS-stimulated macrophages<sup>11</sup>, dexamethasone-stimulated L-cells<sup>5</sup>, and basic fibroblast growth factor-stimulated fibroblasts<sup>12</sup>. In the mouse, 24p3 is a type-1 acute-phase protein, being secreted by hepatocytes in the *in-vivo* turpentine model or in response to TNF- $\alpha$  or dexamethasone *in vitro*<sup>13</sup>.

In disease, NGAL may be moderately raised in bacterial infections because of release from activated neutrophils<sup>14</sup> or from epithelial cells<sup>15</sup>. It may also be moderately raised in atheroma<sup>7</sup> and the ailing myocardium<sup>16</sup>, and in certain epithelial cancers such as those of the mammary gland<sup>17</sup>, gastrointestinal tract<sup>15,18</sup> or urothelium<sup>19</sup>.

### NGAL and acute kidney injury

Apart from the expression of mammalian NGAL that may occur in the above situations, 24p3 undergoes an early and dramatic upregulation in mouse kidney cells after infection with SV40 or polyoma virus. This was in fact the first indication of the existence of NGAL and its early and dramatic response in injured kidney cells<sup>4</sup>.

Years later this finding was extended to post-ischemic<sup>20</sup> and nephrotoxic kidney injury<sup>21</sup>. The marked upregulation of NGAL mRNA and protein levels in the early post-ischemic rat kidney was detected predominantly in proximal tubule cells<sup>20</sup> and NGAL was easily detected by Western blotting of urine after ischemia-reperfusion and cisplatin-induced nephrotoxicity in the mouse<sup>22</sup>.

Urinary NGAL has also been found to be raised in mouse models of diabetic and obstructive nephropathy<sup>23</sup>. However, there is a general paucity of quantitative data on NGAL levels in non-human urine, plasma or serum, whether in the basal state or after kidney injury, and there are as yet no data from the dog. It is the purpose of the present kit to allow such data to be obtained.

In man, it is now widely recognized that NGAL, whether measured in urine or plasma, is the earliest responding marker of acute kidney injury known, with the further advantage that its response is high and easy to measure while retaining proportionality with the severity of injury (see e.g. ref.<sup>24</sup>). It is therefore to be hoped that the determination of urinary or plasma NGAL may become a convenient end-point in dog models of renal injury, nephrotoxicity and other nephropathies.

## PRINCIPLE OF THE ASSAY

The assay is a sandwich ELISA performed in microwells coated with a mouse monoclonal antibody against dog NGAL. Bound NGAL is detected with another mouse monoclonal antibody labeled with biotin and the assay is developed with horseradish peroxidase (HRP)-conjugated streptavidin and a color-forming substrate.

The assay is a four-step procedure:

**Step 1.** Aliquots of calibrators, diluted samples and any controls are incubated in microwells precoated with monoclonal capture antibody. NGAL present in the solutions will bind to the coat, while unbound material is removed by washing.

**Step 2.** Biotinylated monoclonal detection antibody is added to each test well and incubated. The detection antibody attaches to bound NGAL; unbound detection antibody is removed by washing.

**Step 3.** HRP-conjugated streptavidin is added to each test well and allowed to form a complex with the bound biotinylated antibody. Unbound conjugate is removed by washing.

**Step 4.** A color-forming peroxidase substrate containing tetramethylbenzidine (TMB) is added to each test well. The bound HRP-streptavidin reacts with the substrate to generate a blue color. The enzymatic reaction is stopped by adding dilute sulfuric acid (Stop Solution), which changes the color to yellow. The yellow color intensity is read at 450 nm in an ELISA reader. The color intensity (absorbance) is a function of the concentration of NGAL originally added to each well. The results for the calibrators are used to construct a calibration curve from which the concentrations of NGAL in the test samples are read.

**KIT COMPONENTS**

Item	Contents	Quantity
①	Microwell plate, 96 precoated wells	1 plate
②	5x Sample Diluent Conc.	1 x 50 mL
③	Dog NGAL Calibrator 1-8, 0, 4, 10, 20, 40, 100, 200, 400 pg/mL	8 x 1 mL
④	25x Wash Solution Conc.	1 x 40 mL
⑤	Biotinylated Dog-NGAL Antibody	1 x 12 mL
⑥	HRP-Streptavidin	1 x 12 mL
⑦	TMB Substrate	1 x 12 mL
⑧	Stop Solution	1 x 12 mL

**Note:** Liquid reagents contain preservatives and may be harmful if ingested.

**MATERIALS REQUIRED BUT NOT PROVIDED**

- Adjustable micropipettes covering the range 1-1000  $\mu$ L and corresponding disposable pipette tips
- Polypropylene tubes to contain up to 2000  $\mu$ L
- Tube racks
- Adjustable 8- or 12-channel micropipette (50-250  $\mu$ L range) or repeating micropipette (optional)
- Clean 1 L and 250 mL graduated cylinders
- Deionized or distilled water
- Cover for microplate
- Clean container for diluted Wash Solution
- Apparatus for filling wells during washing procedure (optional)
- Lint-free paper towels or absorbent paper
- Disposable pipetting reservoirs
- Timer (60-minute range)
- Calibrated ELISA plate reader capable of reading at 450 nm (preferably subtracting reference values at 650 or 620 nm)
- Sodium hypochlorite (household bleach 1:10

dilution) for decontamination of specimens, reagents, and materials

**PRECAUTIONS****For *in-vitro* research use only**

- This kit should only be used by qualified laboratory staff.
- Use separate pipette tips for each sample, calibrator and reagent to avoid cross-contamination.
- Use separate reservoirs for each reagent. This applies especially to the TMB Substrate.
- After use, decontaminate all samples, reagents and materials by soaking for at least 30 minutes in sodium hypochlorite solution (household bleach diluted 1:10).
- To avoid droplet formation during washing, aspirate the Wash Solution into a bottle containing bleach.
- Dispose of containers and residues safely in accordance with national and local regulations.
- The Stop Solution contains sulfuric acid 0.5 mol/L and can cause irritation or burns to the skin and eyes. If contact occurs, rinse immediately with plenty of water and seek medical advice.
- Do not interchange components from kits with different batch numbers. The components have been standardized as a unit for a given batch.
- Hemolyzed, hyperlipemic, heat-treated or contaminated samples may give erroneous results.
- Do not dilute samples directly in the microwells.
- Do not touch or scrape the bottom of the microwells when pipetting or aspirating fluid.
- Incubation times and temperatures other than those specified may give erroneous results.
- Do not allow the wells to dry once the assay has begun.
- The TMB Substrate is light sensitive. Keep away from bright light.
- Do not reuse microwells or pour reagents back into their bottles once dispensed.

**STABILITY AND STORAGE**

- Store the kit with all reagents at 2-8°C. Do not freeze.

- Use all reagents before the expiry date on the kit box label.

### COLLECTION OF SAMPLES

**Handle and dispose of all blood-derived or urine samples as if they were potentially infectious. See Precautions, sections 1, 2, 4 and 5.**

Determination of NGAL in a single sample requires 10  $\mu\text{L}$  of urine, serum or plasma. Blood samples should be collected into EDTA, heparinized or plain tubes by qualified staff using approved techniques. Plasma or serum should be prepared by standard techniques for laboratory testing. Urine should be centrifuged to remove cellular debris. Cap the prepared samples and freeze them at  $-20^{\circ}\text{C}$  or below if they are not to be analyzed within the next 4 hours. For long-term storage of samples,  $-70^{\circ}\text{C}$  or below is recommended. **Avoid repeated freezing and thawing.** Do not use hemolyzed, hyperlipemic, heat-treated or contaminated samples.

### PREPARATION OF REAGENTS AND SAMPLES

- Bring all samples and reagents to room temperature ( $20\text{-}25^{\circ}\text{C}$ ). Mix samples thoroughly by gentle inversion and if necessary clear visible particulate matter by low-speed centrifugation (discard pellet).
- Wash Solution: Dilute the 25x Wash Solution Conc. by pouring the total contents of the bottle (40 mL) into a 1-L graduated cylinder and add distilled or deionized water to a final volume of 1 L. Mix thoroughly and store at  $2\text{-}8^{\circ}\text{C}$  after use.
- Sample Diluent: Dilute the 5x Sample Diluent Conc. by pouring the total contents of the bottle (50 mL) into a 250-mL graduated cylinder and add distilled or deionized water to a final volume of 250 mL. Mix thoroughly and store at  $2\text{-}8^{\circ}\text{C}$  after use.
- Dog NGAL Calibrators (ready to use): Do not dilute further. The assigned concentration of each calibrator is indicated on its label.
- Biotinylated Dog-NGAL Antibody (ready to use): Do not dilute further.
- HRP-Streptavidin (ready to use): Do not dilute further.
- TMB Substrate (ready to use): Do not dilute further.

- Stop Solution (ready to use): Do not dilute further.
- Samples: Dilute each sample in a recorded proportion with the prediluted Sample Diluent to obtain at least 250  $\mu\text{L}$  of diluted solution that can be set up in duplicate wells at 100  $\mu\text{L}$  per well. An initial screening at a dilution of 1/100 is recommended. This can be prepared in one step, as follows: dilute 10  $\mu\text{L}$  of sample in 990  $\mu\text{L}$  of prediluted Sample Diluent to make a 1/100 dilution. Dilutions are mixed by inversion or moderate vortexing. Out-of-range samples should be re-assayed at higher or lower dilution as appropriate.


### ASSAY PROCEDURE

- Prepare the assay protocol, assigning the appropriate wells for setting up calibrators, diluted samples and any internal laboratory controls in duplicate. If a reference wavelength of 650 or 620 nm is not available on the ELISA reader, a reagent blank well can be assigned. This is set up with 100  $\mu\text{L}$  of prediluted Sample Diluent instead of diluted sample and processed like the other wells.
- Pipette 100  $\mu\text{L}$  volumes of each calibrator dilution, diluted samples and any internal laboratory controls into their corresponding positions in the microwells. Cover the wells and incubate for 60 minutes at room temperature on a shaking platform set at 200/minute.
- Aspirate the contents of the microwells and wash them three times with 300  $\mu\text{L}$  diluted Wash Solution. If the washing is done manually, empty the microwells by inversion and gentle shaking into a suitable container, followed by blotting in the inverted position on a paper towel. A dwell time of 1 minute before emptying is recommended for at least the last wash of the cycle.
- Dispense 100  $\mu\text{L}$  of Biotinylated Dog-NGAL Antibody (ready to use) into each microwell. A multichannel or repeating micropipette can be used. Cover the wells and incubate for 60 minutes at room temperature on a shaking platform set at 200/minute.



5. Wash as described above in Step 3.
6. Dispense 100  $\mu\text{L}$  of HRP-Streptavidin (ready to use) into each microwell. A multichannel or repeating micropipette can be used. Cover the wells and incubate for 60 minutes at room temperature on a shaking platform set at 200/minute.
7. Wash as described above in Step 3.
8. Dispense 100  $\mu\text{L}$  of TMB Substrate (ready to use) into each microwell. The use of a multichannel micropipette is recommended to reduce pipetting time. Start the clock when filling the first well. Cover the wells and incubate for **exactly 10 minutes** at room temperature in the dark.
9. Add 100  $\mu\text{L}$  Stop Solution (ready to use) to each well, maintaining the same pipetting sequence and rate as in Step 8. Mix by gentle shaking for 20 seconds, avoiding splashing. Read the wells within 30 minutes.
10. Read the absorbance values of the wells at 450 nm in an appropriate microplate reader (reference wavelength 650 or 620 nm). If no reference wavelength is available, the value of the reagent blank well is subtracted from each of the other values before other calculations are performed.

#### SCHEMATIC OVERVIEW



## CALCULATION OF RESULTS

This procedure can be performed manually using graph paper with linear x and y axes. NGAL concentrations are drawn and read on the x-axis and the absorbance values on the y-axis. A smooth curve can be drawn through the points obtained for the calibration curve, or adjacent points on the curve can be joined by straight lines. The latter procedure may slightly overestimate or underestimate concentration values between points when the curve is slightly convex to left or right, respectively. Although the curve may approximate to a straight line, it is both practically and theoretically incorrect to calculate and draw the straight line of best fit and to read the results from this.

Results can also be calculated by means of an ELISA reader software program incorporating curve fitting procedures. The procedure of choice is to use linear x and y axes with 4-parameter logistic curve fitting.

Diluted samples that give a mean absorbance above that for the highest Dog NGAL Calibrator or below that for the lowest Dog NGAL Calibrator above zero are out of the range of the assay and their concentrations should be noted as  $>400$  pg/mL and  $<4$  pg/mL, respectively. The corresponding concentrations of the undiluted samples are calculated as  $>(400 \times \text{dilution factor})$  pg/mL and  $<(4 \times \text{dilution factor})$  pg/mL, respectively. If necessary, these samples can be re-assayed at higher and lower dilutions for high- and low-reading samples, respectively.

## VALIDATION OF CALIBRATION CURVE

The mean absorbance value for the 400 pg/mL Dog NGAL Calibrator should be  $>1.5$ . The mean absorbance value for any Dog NGAL Calibrator dilution should be higher than that for the next higher calibrator dilution, e.g. the 200 pg/mL calibrator should give a higher reading than the 100 pg/mL calibrator. The curve should be slightly convex to the left when the results are plotted on linear axes.

**Out-of-line points for individual calibrators:** One or more individual calibrators may give anomalous absorbance readings. One or both of the duplicate

values may be out of line, and the mean of the duplicates may be out of line. This error is significant if it impairs satisfactory curve fitting by the 4-parameter logistic method, which, as a result of the anomalous value, is shifted away from other calibrator points that are in fact correct. The calibrator points and fitted curve should always be examined for correct fit before any calculations of concentration from it are accepted. A poorly fitting curve will also be revealed by a high sum of residual squares. If only one calibrator is affected, which is not the highest calibrator, two courses of action are possible:

i) An erroneous singlet or duplicate result should be eliminated from the curve, and the remaining results refitted by the 4-parameter logistic procedure. If a satisfactory fit is obtained, provisional concentration results can be calculated from it.

ii) If no satisfactory fit can be obtained in this way, but the curve is otherwise consistent, provisional results can be obtained from straight lines or simple cubic spline fitting between the means of duplicates, omitting the erroneous point.

If two or more calibrators are affected, the assay should be repeated.

## QUALITY CONTROL

Laboratories intending to perform repeated assays should establish their own high-reading and low-reading control samples, stored in small (e.g. 50- $\mu$ L) aliquots at  $-70^{\circ}\text{C}$  or below.

An aliquot of each should be thawed and tested in each assay and a record kept of successive results. This serves as a control of test performance, test integrity and operator reliability.

The results should be examined for drift (tendency for successive results to rise or fall) or significant deviation from the mean of previous results. Values not deviating by more than 20% from the mean of previous values can be taken to indicate acceptability of the assay.

Aliquots of control samples should not be refrozen for repeated assay once thawed, and if a further assay is performed, fresh control aliquots and fresh dilutions of samples should be used.

**EXPECTED RESULTS**

Absolute concentrations of NGAL in dog urine, serum or plasma are not known, as results obtained by immunochemical techniques have not been standardized to an accepted purified preparation of dog NGAL of known gravimetric concentration. Normal values have yet to be assigned to urine, plasma and serum concentrations of NGAL in different strains of dogs.

**PERFORMANCE CHARACTERISTICS**

**Limit of detection:** The lowest concentration of dog NGAL giving an absorbance reading greater than 2 SD above the mean zero (Calibrator 1) reading was 0.56 pg/mL, which is significantly lower than the value of the lowest calibrator concentration above zero (4 pg/mL).

**Intraassay (within-run) and interassay (between-run) reproducibility:** Dilutions of two dog urine samples (U1, U2) and two dog plasma samples (P1, P2) were run in 8 replicates for determining within-run reproducibility and in replicates in 16 assays on different days for determining between-run reproducibility. The following results were obtained (CV = coefficient of variation):

Sample	Mean NGAL conc. (ng/mL)	CV within-run	CV between-run
U1	9.4	2%	5%
U2	6.1	1%	9%
P1	12.8	2%	7%
P2	13.7	3%	8%

**Analytical recovery:** Four different dilutions of urine (U1-4) and plasma (P1-4) were spiked with calibrator material and analyzed in the assay after appropriate further dilution. Recovery was calculated as ("Measured"/"Calculated") x 100%:

Sample	Measured (pg/mL)	Calculated (pg/mL)	Recovery
U1	52.6	53.1	99%
U2	89.9	93.2	96%
U3	182	178	102%
U4	365	337	108%
Mean recovery (U)			101%
P1	48.4	52.7	92%
P2	93.8	92.8	101%
P3	174	177	98%
P4	348	337	103%
Mean recovery (P)			99%

**Linearity:** Dog NGAL was measured in serial dilutions (n = 8) of two urine samples and two plasma samples. The CV of the mean of the measured values corrected for the dilution was 3% for both urine samples and 5% for both plasma samples.

**Specificity:** The two mouse monoclonal antibodies used in this assay were raised against recombinant dog NGAL and react with the peak of recombinant dog NGAL and the 25-kDa peak of native NGAL from dog serum subjected to molecular size exclusion chromatography.

**LIABILITY****For *in-vitro* research use only.**

This kit is intended only for the *in-vitro* determination of dog NGAL in urine, plasma, serum, tissue extracts or culture media.

The kit is intended only for use by qualified personnel carrying out research.

If the recipient of this kit passes it on in any way to a third party, this instruction must be enclosed, and said recipient shall at own risk secure in favor of BioPorto Diagnostics A/S all limitations of liability herein.

BioPorto Diagnostics A/S shall not be responsible for any damages or losses due to using the kit in any way other than as expressly stated in these Instructions.

The liability of BioPorto Diagnostics A/S shall in no event exceed the commercial value of the kit.

BioPorto Diagnostics A/S shall under no circumstances be liable for indirect, special or consequential damages, including but not limited to loss of profit.

**REFERENCES**

1. Kjeldsen L, Cowland JB, Borregaard N (2000) Human neutrophil gelatinase-associated lipocalin and homologous proteins in rat and mouse. *Biochim Biophys Acta* 1482:272-283.
2. Flower DR (1996) The lipocalin protein family: structure and function. *Biochem J* 318:1-14.
3. Goetz DH, Holmes MA, Borregaard N, Bluhm ME, Raymond KN, Strong RK (2002) The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. *Mol Cell* 10:1033-1043.
4. Hraba-Renevey S, Turler H, Kress M, Salomon C, Weil R (1989) SV40-induced expression of mouse gene 24p3 involves a post-transcriptional mechanism. *Oncogene* 4:601-608.
5. Garay-Rojas E, Harper M, Hraba-Renevey S, Kress M (1996) An apparent autocrine mechanism amplifies the dexamethasone- and retinoic acid-induced expression of mouse lipocalin-encoding gene 24p3. *Gene* 170:173-180.
6. Zhao H, Ito A, Sakai N, Matsuzawa Y, Yamashita S, Nojima H (2006) RECS1 is a negative regulator of matrix metalloproteinase-9 production and aged RECS1 knockout mice are prone to aortic dilation. *Circ J* 70:615-624.
7. Hemdahl AL, Gabrielsen A, Zhu C, Eriksson P, Hedin U, Kastrup J, Thorén P, Hansson GK (2006) Expression of neutrophil gelatinase-associated lipocalin in atherosclerosis and myocardial infarction. *Arterioscler Thromb Vasc Biol* 26:136-142.
8. Liu Q, Ryon J, Nilsen-Hamilton M (1997) Uterocalin: a mouse acute phase protein expressed in the uterus around birth. *Mol Reprod Dev.* 46:507-514.
9. Huang HL, Chu ST, Chen YH (1999) Ovarian steroids regulate 24p3 expression in mouse uterus during the natural estrous cycle and the preimplantation period. *J Endocrinol* 162:11-19.
10. Huang HL, Chen JM, Chen YH (1996) Demonstration of a glycoprotein derived from the 24p3 gene in mouse uterine luminal fluid. *Biochem J* 316:545-550.

11. Meheus LA, Fransen LM, Raymackers JG, Blockx HA, Van Beeumen JJ, Van Bun SM, Van de Voorde A (1993) Identification by microsequencing of lipopolysaccharide-induced proteins secreted by mouse macrophages. *J Immunol* 151:1535-1547.
12. Davis TR, Tabatabai L, Bruns K, Hamilton RT, Nilsen-Hamilton M (1991) Basic fibroblast growth factor induces 3T3 fibroblasts to synthesize and secrete a cyclophilin-like protein and beta 2-microglobulin. *Biochim Biophys Acta* 1095:145-152.
13. Liu Q, Nilsen-Hamilton M (1995) Identification of a new acute phase protein. *J Biol Chem* 270:22565-22570.
14. Xu S, Venge P (2000) Lipocalins as biochemical markers of disease. *Biochim Biophys Acta* 1482:298-307.
15. Alpizar-Alpizar W, Laerum OD, Illemann M, Ramirez JA, Arias A, Malespín-Bendaña W, Ramirez V, Lund LR, Borregaard N, Nielsen BS (2009) Neutrophil gelatinase-associated lipocalin (NGAL/Lcn2) is upregulated in gastric mucosa infected with *Helicobacter pylori*. *Virchows Arch* 455:225-233.
16. Yndestad A, Landro L, Ueland T, Dahl CP, Flo TH, Vinge LE, Espevik T, Frøland SS, Husberg C, Christensen G, Dickstein K, Kjekshus J, Øie E, Gullestad L, Aukrust P (2009) Increased systemic and myocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failure. *Eur Heart J* 30:1229-1236.
17. Stoesz SP, Friedl A, Haag JD, Lindstrom MJ, Clark GM, Gould MN (1998) Heterogeneous expression of the lipocalin NGAL in primary breast cancers. *Int J Cancer* 79:565-572.
18. Nielsen BS, Borregaard N, Bundgaard JR, Timshel S, Sehested M, Kjeldsen L (1996) Induction of NGAL synthesis in epithelial cells of human colorectal neoplasia and inflammatory bowel diseases. *Gut* 38:414-420.
19. Monier F, Surla A, Guillot M, Morel F (2000) Gelatinase isoforms in urine from bladder cancer patients. *Clin Chim Acta* 299:11-23.
20. Matthaeus T, Schulze-Lohoff E, Ichimura T, Weber M, Andreucci M, Park KM, Alessandrini A, Bonventre JV (2001) Co-regulation of neutrophil gelatinase-associated lipocalin and matrix metalloproteinase-9 in the posts ischemic rat kidney. *J Am Soc Nephrol* 12:787A (abstract no. 4112).
21. Mishra J, Mori K, Ma Q, Kelly C, Barasch J, Devarajan P (2004) Neutrophil gelatinase-associated lipocalin: a novel early urinary biomarker for cisplatin nephrotoxicity. *Am J Nephrol* 24:307-315.
22. Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, Yang J, Barasch J, Devarajan P (2003) Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. *J Am Soc Nephrol* 14:2534-2543.
23. AL Kuwabara T, Mori K, Mukoyama M, Kasahara M, Yokoi H, Saito Y, Yoshioka T, Ogawa Y, Imamaki H, Kusakabe T, Ebihara K, Omata M, Satoh N, Sugawara A, Barasch J, Nakao K (2009) Urinary neutrophil gelatinase-associated lipocalin levels reflect damage to glomeruli, proximal tubules, and distal nephrons. *Kidney Int* 75:285-294.
24. Bolignano D, Donato V, Coppolino G, Campo S, Buemi A, Lacquaniti A, Buemi M (2008) Neutrophil gelatinase-associated lipocalin (NGAL) as a marker of kidney damage. *Am J Kidney Dis* 52:595-605.



Catalogue number



Caution, consult accompanying documents



Batch code



Biological risk



Consult instructions for use



Do not use if package is damaged



Use by

**WASH SOLUTION 25X**Concentrated Wash Solution.  
Dilute before use.

Manufacturer

**SAMPLE DILUENT 5X**Concentrated Sample  
Diluent. Dilute before use.

Keep away from sunlight



Temperature limitation



Do not reuse

## Related products

Cat. No.	Product name
KIT 036	NGAL ELISA Kit
KIT 037	NGAL Rapid ELISA Kit
KIT 042	Mouse NGAL ELISA Kit
KIT 044	Pig NGAL ELISA Kit
KIT 046	Rat NGAL ELISA Kit



**BIOPORTO**<sup>®</sup>  
Diagnostics



BioPorto Diagnostics A/S  
Grusbakken 8  
DK-2820 Gentofte  
Denmark

Phone (+45) 4529 0000  
Fax (+45) 4529 0001  
E-mail [info@bioporto.com](mailto:info@bioporto.com)  
Web [www.bioporto.com](http://www.bioporto.com)  
[www.ngal.com](http://www.ngal.com)